The AGC Group is a large multinational conglomerate founded in 1907, with a vast network of over 200 companies operating in more than 30 countries. Among its diverse business interests such as Glass, Chemicals and Electronics, AGC places significant emphasis on its Life Science business, which is considered one of the most strategic areas for the company.
Benefits for AGC Pharma Chemicals Customers:
Financial stability and backing of a global organization
Long-term vision and strategic plan for AGC Pharma Chemicals
Access to capital to expand global capabilities and capacity
1.907
Year of Founding
56,700
Employees
194
Worldwide Sites
13,300
Net Sales
FINANCIAL STABILITY
847,000
Operating Profit
Life Science Company of the AGC Group
As a strategic cornerstone, the Life Science Company of the AGC Group is engaged in global life science business, centering on contract development and manufacturing organization (CDMO) activities, where we develop manufacturing processes for and manufacture pharmaceutical and agrochemical components. We provide services in a wide range of fields, from synthetic pharmaceuticals and agrochemicals that leverage fluorination technologies historically fostered in AGC’s other businesses, to biopharmaceuticals – the demand for which has grown globally – as well as leading-edge cell and gene therapies, and messenger RNAs. AGC Pharma Chemicals, a subsidiary within this segment, plays a crucial role by focusing on the production and process development of small molecules (pharmaceutical chemicals), making it an integral part of AGC’s broader strategy in the life sciences sector.
Global Network of AGC Life Science
The group has over 40 years of CDMO experience. Through acquisitions and investments, Life Science has become a strategic cornerstone, with a highly integrated cGMP* system with 10 sites in three regions in Japan, the United States and Europe. We provide the same high standard of development and manufacturing services from any region and in a wide range of fields (*Current Good Manufacturing Practice).
AGC Life Science Global CDMO Sites
AGC Pharma Chemicals
AGC acquired the former API plant of Boehringer Ingelheim in Malgrat de Mar, Barcelona, Spain. The plant has been operational as AGC Pharma Chemicals Europe, S.L.U. since 1 March 2019 as the FDA registered site in Europe for AGC to help broaden its pharmaceutical CDMO business. The company is an innovative Contract Development and Manufacturing Organization (CDMO) serving the global pharmaceutical industry with small molecule APIs and Intermediates.
AGC Biologics
AGC Biologics is a global CDMO based in Seattle, Washington, USA. The company provides pharmaceutical development and manufacturing services for protein-based biologics and cell and gene therapies. With seven facilities and teams of scientists across three continents, we have the resources and the available capacity you need to accelerate your race to GMP. From development to clinical trials, to full-scale commercialization, we can help you reach your goals at any stage in the drug development and manufacturing process.
We specialize in the following modalities and substances, mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our services range from process development, analytical development, cGMP manufacturing, quality control and quality assurance, and process validation.
We forge exceptionally strong partnerships with our customers, and we never lose sight of our commitment to delivering reliable and compliant drug substances.
AGC Chiba Japan
Established in 1959 on the waterfront industrial park in Ichihara City, Chiba Prefecture, the cGMP plant started in January 2009.
As AGC Pharma Chemicals (Small Molecule CDMO), we have two cGMP plants supporting clinical phase projects and high-volume commercial phase manufacturing for APIs and Intermediates (the reactor size range is from 1m3 to 15m3) with cryogenic (-100ºC) and GMP Micronizer capability.
YTC (Yokohama Technical Center) R&D center in Japan
YTC is the center of global innovation within AGC. It integrates an R&D area for small molecule CDMO, including HAPI handling. A new 20,000 m² facility is planned, featuring mammalian cell culture, YTC is the center of global innovation within AGC. It integrates an R&D area for small molecule CDMO, including HAPI handling. In YTC, we have over 400 chemists for Chemicals & Life Science businesses. A new 20,000 m² facility is planned, featuring mammalian cell culture, messenger RNA and cell therapy services, that will become operational in 2026.
AGC Wakasa Chemicals
We have two plants with non-GMP unit for registered starting materials, raw materials, and agrochemicals (the reactor size range is from 0.1m3 to 15m3) with cryogenic (-100ºC) capability. On top of this, we have cGMP compliant unit for prostaglandins.
